Why HbA1c remains the pragmatic choice for monitoring in India's public health system
Abstract
We read with interest the Viewpoint by Samajdar et al. regarding the limitations of HbA1c for monitoring diabetes in South Asia.1 While acknowledging the risk for misclassification, we contend that excluding HbA1c (glycated haemoglobin) from India's public healthcare system would exacerbate gaps in the diabetes care cascade by undermining diagnostic consistency and longitudinal monitoring for those seeking public care.
Fields of Study & Subjects
Diabetes
Cardiovascular Risks
and Lipoproteins
Diabetes Management and Education
Hemoglobinopathies and Related Disorders
Publication details
- Journal / source
- The Lancet Regional Health - Southeast Asia
- Publisher
- Elsevier BV
- Volume
- 47
- Pages
- 100756–100756
- Publication date
- 1 April 2026
- Language
- EN